The importance of PD-L1 diagnostic assay harmonization for the selection of lung cancer immunotherapy

J Thorac Dis. 2018 Nov;10(Suppl 33):S4096-S4100. doi: 10.21037/jtd.2018.10.24.

Juan-Manuel Hernandez-Martinez^{1

2}, Zyanya Lucia Zatarain-Barrón¹, Andrés F Cardona^{3

4

5}, Oscar Arrieta¹

¹ Thoracic Oncology Unit and Experimental Oncology Laboratory, Instituto Nacional de Cancerología de México (INCan), Mexico City, Mexico.
² CONACYT-Instituto Nacional de Cancerología, Mexico City, Mexico.
³ Clinical and Translational Oncology Group, Clinica del Country, Bogotá, Colombia.
⁴ Foundation for Clinical and Applied Cancer Research (FICMAC), Bogotá, Colombia.
⁵ Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, Bogotá, Colombia.

No abstract available

Publication types